Welcome to LookChem.com Sign In|Join Free

CAS

  • or
1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one is a substituted benzazepinone derivative, which is a type of organic compound with a unique chemical structure. It is characterized by the presence of a benzazepine ring system with two methoxy groups attached to the 7th and 8th positions, and a carbonyl group at the 2nd position. 1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one has potential applications in various fields, particularly in the pharmaceutical industry.

73942-87-7 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 73942-87-7 Structure
  • Basic information

    1. Product Name: 1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one
    2. Synonyms: Ivabradine Impurity 13;7,8-Dimethoxy-1H-benzo[d]azepin-2(3H)-one;1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one;7,8-dimethoxy-1, 3-dihydro-2H-benzo[d] azepin-2-one;7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one;2H-3-Benzazepin-2-one,1,3-dihydro-7,8-diMethoxy-;1,3-Dihydro-7,8-dimethoxybenzo[d]azepin-2-one;7,8-diMethoxy-2,3-dihydro-1H-3-benzazepin-2-one
    3. CAS NO:73942-87-7
    4. Molecular Formula: C12H13NO3
    5. Molecular Weight: 219.24
    6. EINECS: 1806241-263-5
    7. Product Categories: Aromatics;Heterocycles;Intermediates
    8. Mol File: 73942-87-7.mol
  • Chemical Properties

    1. Melting Point: 244.0 to 248.0 °C
    2. Boiling Point: 455.8 °C at 760 mmHg
    3. Flash Point: 229.5 °C
    4. Appearance: /
    5. Density: 1.167
    6. Vapor Pressure: 1.7E-08mmHg at 25°C
    7. Refractive Index: 1.546
    8. Storage Temp.: Sealed in dry,Room Temperature
    9. Solubility: Chloroform (Slightly), DMSO (Slightly)
    10. PKA: 13.29±0.20(Predicted)
    11. CAS DataBase Reference: 1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one(CAS DataBase Reference)
    12. NIST Chemistry Reference: 1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one(73942-87-7)
    13. EPA Substance Registry System: 1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one(73942-87-7)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 73942-87-7(Hazardous Substances Data)

73942-87-7 Usage

Uses

Used in Pharmaceutical Industry:
1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one is used as a key intermediate in the synthesis of bradycardic agents, which are medications that help to slow down the heart rate. These agents are useful in the treatment of various cardiovascular conditions, such as tachycardia, arrhythmias, and hypertension.
Additionally, 1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one is used as a precursor in the development of isoform-selective f-current blockers. These blockers are compounds that selectively inhibit specific isoforms of the fast sodium current (f-current) in cardiac cells, which can be beneficial in the management of certain cardiac arrhythmias.

Check Digit Verification of cas no

The CAS Registry Mumber 73942-87-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,3,9,4 and 2 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 73942-87:
(7*7)+(6*3)+(5*9)+(4*4)+(3*2)+(2*8)+(1*7)=157
157 % 10 = 7
So 73942-87-7 is a valid CAS Registry Number.
InChI:InChI=1/C12H13NO3/c1-15-10-5-8-3-4-13-12(14)7-9(8)6-11(10)16-2/h3-6H,7H2,1-2H3,(H,13,14)

73942-87-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

1.2 Other means of identification

Product number -
Other names 7,8-dimethoxy-1,3-dihydro-3-benzazepin-2-one

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:73942-87-7 SDS

73942-87-7Synthetic route

7,8-dimethoxy-3-(4-methoxybenzyl)-1,3-dihydro-2H-3-benzazepin-2-one

7,8-dimethoxy-3-(4-methoxybenzyl)-1,3-dihydro-2H-3-benzazepin-2-one

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

Conditions
ConditionsYield
With trifluoroacetic acid for 8h; Reflux;97%
N-(2,2-dimethoxy-ethyl)-3,4-dimethoxyphenylacetamide
73954-34-4

N-(2,2-dimethoxy-ethyl)-3,4-dimethoxyphenylacetamide

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

Conditions
ConditionsYield
With hydrogenchloride; acetic acid In water at 25℃; for 17h;77.5%
With hydrogenchloride; acetic acid for 17h; Ambient temperature;75%
With hydrogenchloride; acetic acid In water at 20℃; for 8h;61.4%
(3,4-Dimethoxyphenyl)acetic acid
93-40-3

(3,4-Dimethoxyphenyl)acetic acid

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 81 percent / thionyl chloride / CH2Cl2 / 1 h / Heating
2: triethylamine / CH2Cl2 / 1 h / Ambient temperature
3: 75 percent / glacial acetic acid, conc. HCl / 17 h / Ambient temperature
View Scheme
Multi-step reaction with 2 steps
1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; benzotriazol-1-ol
2: hydrogenchloride; acetic acid / water
View Scheme
Multi-step reaction with 2 steps
1: toluene / 30 h / Reflux
2: hydrogenchloride; sulfuric acid / water / 4 h / 25 - 30 °C / Reflux
View Scheme
Multi-step reaction with 3 steps
1: thionyl chloride / dichloromethane
2: triethylamine / dichloromethane
3: hydrogenchloride; acetic acid
View Scheme
Multi-step reaction with 2 steps
1: O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; triethylamine / N,N-dimethyl-formamide / 20 °C / Inert atmosphere
2: phosphorus pentaoxide / methanesulfonic acid / 20 °C / Inert atmosphere
View Scheme
3,4-dimethoxyphenylacetyl chloride
10313-60-7

3,4-dimethoxyphenylacetyl chloride

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: triethylamine / CH2Cl2 / 1 h / Ambient temperature
2: 75 percent / glacial acetic acid, conc. HCl / 17 h / Ambient temperature
View Scheme
Multi-step reaction with 2 steps
1: triethylamine / dichloromethane
2: hydrogenchloride; acetic acid
View Scheme
7,8-dimethoxy-3-(4-methoxybenzyl)-1H-3-benzazepine-2,4(3H,5H)-dione

7,8-dimethoxy-3-(4-methoxybenzyl)-1H-3-benzazepine-2,4(3H,5H)-dione

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: lithium triethylborohydride / tetrahydrofuran / 1.5 h / -78 °C
1.2: -78 - 20 °C
2.1: trifluoroacetic acid / 8 h / Reflux
View Scheme
7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepine-2,4-dione
85175-49-1

7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepine-2,4-dione

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: potassium carbonate; potassium iodide / acetonitrile / 27.5 h / 80 °C
2.1: lithium triethylborohydride / tetrahydrofuran / 1.5 h / -78 °C
2.2: -78 - 20 °C
3.1: trifluoroacetic acid / 8 h / Reflux
View Scheme
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

(4,5-dimethoxy-2-iodophenyl)methyl bromide
293732-19-1

(4,5-dimethoxy-2-iodophenyl)methyl bromide

3-(2-iodo-4,5-dimethoxybenzyl)-7,8-dimethoxy-1,3-dihydrobenzo[d]azepin-2-one
1104967-37-4

3-(2-iodo-4,5-dimethoxybenzyl)-7,8-dimethoxy-1,3-dihydrobenzo[d]azepin-2-one

Conditions
ConditionsYield
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With potassium tert-butylate In N,N-dimethyl-formamide at 0℃; for 0.5h;
Stage #2: (4,5-dimethoxy-2-iodophenyl)methyl bromide In N,N-dimethyl-formamide at 20℃; for 2h;
98%
1-bromo-3-chloro-2-methyl propane
6974-77-2

1-bromo-3-chloro-2-methyl propane

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

1-(7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-on-3-yl)-2-methyl-3-chloro-propane
85176-88-1

1-(7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-on-3-yl)-2-methyl-3-chloro-propane

Conditions
ConditionsYield
97.5%
With potassium tert-butylate 1.) DMSO, RT, 30 min, 2.) RT, 30 min; Multistep reaction;
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

epichlorohydrin
106-89-8

epichlorohydrin

1-(7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-on-3-yl)-2,3-epoxy-propane
85176-49-4

1-(7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-on-3-yl)-2,3-epoxy-propane

Conditions
ConditionsYield
94.5%
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

1,3-chlorobromopropane
109-70-6

1,3-chlorobromopropane

3-(3-chloropropyl)-1,3-dihydro-7,8-dimethoxy-2H-3-benzazepine-2-one
85175-59-3

3-(3-chloropropyl)-1,3-dihydro-7,8-dimethoxy-2H-3-benzazepine-2-one

Conditions
ConditionsYield
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With potassium tert-butylate In dimethyl sulfoxide at 25 - 30℃; for 0.5h;
Stage #2: 1.3-chlorobromopropane In dimethyl sulfoxide at 15 - 20℃; for 0.5h; Reagent/catalyst; Time; Temperature; Concentration;
89%
87.3%
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With sodium hydride In N,N-dimethyl-formamide for 0.5h;
Stage #2: 1.3-chlorobromopropane In N,N-dimethyl-formamide at 20℃; for 10.5h;
66.5%
2-bromo-2-(2-ethyl)dioxolane
18742-02-4

2-bromo-2-(2-ethyl)dioxolane

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

3-(2-[1,3]-dioxolan-2-yl-ethyl)-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

3-(2-[1,3]-dioxolan-2-yl-ethyl)-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

Conditions
ConditionsYield
With sodium hydroxide In 1-methyl-pyrrolidin-2-one; water at 2 - 60℃; for 3h; Product distribution / selectivity;87%
With potassium carbonate In 1-methyl-pyrrolidin-2-one at 130℃; for 9h; Product distribution / selectivity;80%
(S)-3-chloro-N-((3,4-dimethoxybicyclo[4.2,0]octa-1(6),2,4-trien-7-yl)methyl)-N-methylpropan-1-amine
1031767-71-1

(S)-3-chloro-N-((3,4-dimethoxybicyclo[4.2,0]octa-1(6),2,4-trien-7-yl)methyl)-N-methylpropan-1-amine

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-(methyl)amino]propyl}-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
1086026-31-4

3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-(methyl)amino]propyl}-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

Conditions
ConditionsYield
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With potassium tert-butylate In dimethyl sulfoxide at 20℃; for 0.5h;
Stage #2: (S)-3-chloro-N-((3,4-dimethoxybicyclo[4.2,0]octa-1(6),2,4-trien-7-yl)methyl)-N-methylpropan-1-amine In dimethyl sulfoxide at 20℃;
87%
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

4-chloromethyl-1,2-dimethoxy-benzene
7306-46-9

4-chloromethyl-1,2-dimethoxy-benzene

3-(3,4-dimethoxybenzyl)-7,8-dimethoxy-1,3-dihydrobenzo[d]azepin-2-one
1104967-46-5

3-(3,4-dimethoxybenzyl)-7,8-dimethoxy-1,3-dihydrobenzo[d]azepin-2-one

Conditions
ConditionsYield
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With potassium tert-butylate In N,N-dimethyl-formamide at 0℃; for 0.5h;
Stage #2: 4-chloromethyl-1,2-dimethoxy-benzene In N,N-dimethyl-formamide at 20℃; for 2h;
86%
2-(3,4-dimethoxyphenyl)-1-iodoethane
64728-23-0

2-(3,4-dimethoxyphenyl)-1-iodoethane

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

3-[2-(3,4-dimethoxyphenyl)ethyl]-7,8-dimethoxy-1,3-dihydrobenzo[d]azepin-2-one
1104967-34-1

3-[2-(3,4-dimethoxyphenyl)ethyl]-7,8-dimethoxy-1,3-dihydrobenzo[d]azepin-2-one

Conditions
ConditionsYield
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With potassium tert-butylate In N,N-dimethyl-formamide at 0℃; for 0.5h;
Stage #2: 2-(3,4-dimethoxyphenyl)-1-iodoethane In N,N-dimethyl-formamide at 20℃; for 2h;
77%
With potassium tert-butylate In N,N-dimethyl-formamide
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

N-(tert-butoxycarbonyl)-N-methyl-3-chloropropylamine
114326-14-6

N-(tert-butoxycarbonyl)-N-methyl-3-chloropropylamine

tert-Butyl [3-(7,8-dimethoxy-2-oxo-1,2-dihydro-3H-3-benzazepin-3-yl)propyl]-methylcarbamate
1232191-37-5

tert-Butyl [3-(7,8-dimethoxy-2-oxo-1,2-dihydro-3H-3-benzazepin-3-yl)propyl]-methylcarbamate

Conditions
ConditionsYield
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With sodium hydride In N,N-dimethyl-formamide; mineral oil at 25℃; for 1h;
Stage #2: N-(tert-butoxycarbonyl)-N-methyl-3-chloropropylamine In minreal oil; N,N-dimethyl-formamide at 50℃;
77%
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With sodium hydride In N,N-dimethyl-formamide; oil at 25℃; for 1h;
Stage #2: N-(tert-butoxycarbonyl)-N-methyl-3-chloropropylamine In N,N-dimethyl-formamide; oil at 50℃;
77%
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

C16H21NO6S

C16H21NO6S

C27H30N2O6

C27H30N2O6

Conditions
ConditionsYield
In toluene at 110 - 130℃; for 6h; Solvent; Temperature;63.5%
3-chloromethyl-N-[2-(6-methyl-pyrid-2-yl)-ethyl]-pyrrolidine
119919-47-0

3-chloromethyl-N-[2-(6-methyl-pyrid-2-yl)-ethyl]-pyrrolidine

potassium tert-butylate
865-47-4

potassium tert-butylate

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

3-[(N-(2-(6-Methyl-pyrid-2-yl)-ethyl)-pyrrolidin-3-yl)methyl]-7,8-dimethoxy-2-oxo-1,3-dihydro-2H-3-benzazepinedihydrochloride

3-[(N-(2-(6-Methyl-pyrid-2-yl)-ethyl)-pyrrolidin-3-yl)methyl]-7,8-dimethoxy-2-oxo-1,3-dihydro-2H-3-benzazepinedihydrochloride

Conditions
ConditionsYield
In dimethyl sulfoxide61%
trans-1,4-dichlorobut-2-ene
110-57-6

trans-1,4-dichlorobut-2-ene

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

trans-3-(4-chloro-2-butenyl)-7,8-dimethoxy-1,3-dihydro-2H-benzo[d]azepin-2-one

trans-3-(4-chloro-2-butenyl)-7,8-dimethoxy-1,3-dihydro-2H-benzo[d]azepin-2-one

Conditions
ConditionsYield
With potassium tert-butylate In dimethyl sulfoxide at 20℃; for 1h;48%
With potassium tert-butylate In dimethyl sulfoxide at 20℃; Inert atmosphere;
Z-1,4-dichlorobutene
1476-11-5

Z-1,4-dichlorobutene

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

A

3-((Z)-4-chlorobut-2-en-1-yl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one
1245568-10-8

3-((Z)-4-chlorobut-2-en-1-yl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one

B

3,3'-((Z)-but-2-ene-1,4-diyl)bis(7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one)
1245568-12-0

3,3'-((Z)-but-2-ene-1,4-diyl)bis(7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one)

Conditions
ConditionsYield
With potassium tert-butylate In dimethyl sulfoxide at 20℃; Inert atmosphere;A 30%
B 6%
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

1-Bromo-2-chloroethane
107-04-0

1-Bromo-2-chloroethane

1-(7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-on-3-yl)-2-chloro-ethane
85176-62-1

1-(7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-on-3-yl)-2-chloro-ethane

Conditions
ConditionsYield
20%
1-bromo-3-chloro-propan-2-ol
4540-44-7

1-bromo-3-chloro-propan-2-ol

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

3-(3-Chloro-2-hydroxy-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

3-(3-Chloro-2-hydroxy-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

Conditions
ConditionsYield
With potassium tert-butylate 1.) DMSO, RT, 30 min, 2.) RT, 30 min; Multistep reaction;
4-chlorobutyl bromide
6940-78-9

4-chlorobutyl bromide

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

3-(4-Chloro-butyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one
85176-24-5

3-(4-Chloro-butyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

Conditions
ConditionsYield
With potassium tert-butylate 1.) DMSO, RT, 30 min, 2.) RT, 30 min; Multistep reaction;
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

3-((E)-4-{[2-(3,4-dimethoxyphenyl)ethyl]methylamino}but-2-enyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

3-((E)-4-{[2-(3,4-dimethoxyphenyl)ethyl]methylamino}but-2-enyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 48 percent / t-BuOK / dimethylsulfoxide / 1 h / 20 °C
2: 53 percent / Et3N / 5 h / 60 °C
View Scheme
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

1-(7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-on-3-yl)-2-chloro-ethane
85176-62-1

1-(7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-on-3-yl)-2-chloro-ethane

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min
2: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min
View Scheme
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

7,8-Dimethoxy-3-[3-(methyl-phenethyl-amino)-propyl]-1,3-dihydro-benzo[d]azepin-2-one

7,8-Dimethoxy-3-[3-(methyl-phenethyl-amino)-propyl]-1,3-dihydro-benzo[d]azepin-2-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min
2: 2 h / 90 - 95 °C
View Scheme
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

7,8-Dimethoxy-3-[3-(methyl-phenethyl-amino)-propyl]-1,3,4,5-tetrahydro-benzo[d]azepin-2-one
92452-47-6

7,8-Dimethoxy-3-[3-(methyl-phenethyl-amino)-propyl]-1,3,4,5-tetrahydro-benzo[d]azepin-2-one

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min
2: 2 h / 90 - 95 °C
3: H2 / Pd/C / acetic acid / 10 h / 3750.3 Torr / Ambient temperature
View Scheme
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

3-(3-{[2-(4-Chloro-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

3-(3-{[2-(4-Chloro-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min
2: 2 h / 90 - 95 °C
View Scheme
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

3-(3-{[2-(4-Hydroxy-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

3-(3-{[2-(4-Hydroxy-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min
2: 2 h / 90 - 95 °C
View Scheme
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

3-(3-{[2-(4-Amino-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one
85176-42-7

3-(3-{[2-(4-Amino-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min
2: 2 h / 90 - 95 °C
View Scheme
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

7,8-Dimethoxy-3-(3-{[2-(4-methoxy-phenyl)-ethyl]-methyl-amino}-propyl)-1,3-dihydro-benzo[d]azepin-2-one
85175-70-8

7,8-Dimethoxy-3-(3-{[2-(4-methoxy-phenyl)-ethyl]-methyl-amino}-propyl)-1,3-dihydro-benzo[d]azepin-2-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min
2: 2 h / 90 - 95 °C
View Scheme
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

1-[7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-on-3-yl]-3-[N-methyl-N-(2-{4-amino-phenyl}-ethyl)-amino]-propane
85175-81-1

1-[7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-on-3-yl]-3-[N-methyl-N-(2-{4-amino-phenyl}-ethyl)-amino]-propane

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min
2: 2 h / 90 - 95 °C
3: H2 / Pd/C / acetic acid / 10 h / 3750.3 Torr / Ambient temperature
View Scheme
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

3-(3-{[2-(4-Dimethylamino-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

3-(3-{[2-(4-Dimethylamino-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min
2: 2 h / 90 - 95 °C
View Scheme
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
73942-87-7

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

3-(3-{[2-(3,4-Dichloro-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

3-(3-{[2-(3,4-Dichloro-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min
2: 2 h / 90 - 95 °C
View Scheme

73942-87-7Relevant articles and documents

Design of oxa-spirocyclic PHOX ligands for the asymmetric synthesis of lorcaserin: Via iridium-catalyzed asymmetric hydrogenation

Ye, Xiang-Yu,Liang, Zhi-Qin,Jin, Cong,Lang, Qi-Wei,Chen, Gen-Qiang,Zhang, Xumu

, p. 195 - 198 (2021/01/14)

Phosphine-oxazoline (PHOX) ligands are a very important class of privileged ligands in asymmetric catalysis. A series of highly rigid oxa-spiro phosphine-oxazoline (O-SIPHOX) ligands based on O-SPINOL was synthesized efficiently, and their iridium complexes were synthesized by coordination of the O-SIPHOX ligands to [Ir(cod)Cl]2 in the presence of sodium tetrakis-3,5-bis(trifluoromethyl)phenylborate (NaBArF). The cationic iridium complexes showed high reactivity and excellent enantioselectivity in the asymmetric hydrogenation of 1-methylene-tetrahydro-benzo[d]azepin-2-ones (up to 99% yield and up to 99% ee). A key intermediate of the anti-obesity drug lorcaserin could be efficiently synthesized using this protocol.

PROCESS FOR THE PREPARATION OF BENZAZEPINE-2-ONE DERIVATIVE

-

, (2017/09/05)

The present, invention relates to a cost effective, environment friendly industrially viable process for the preparation of 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepine-2-one, an intermediate used in the preparation of ivabradine, without using acid chloride intermediate and condensing agent.

Benzo aza compound, preparation method and use thereof

-

Paragraph 0109; 0110, (2017/08/22)

Belonging to the field of pharmaceutical chemistry, the invention relates to a benzoazepine compound, a preparation method and application thereof, in particular to the benzoazepine compound, its preparation method and application in the field of treatment of nervous system diseases, especially application in the field of drug addiction related to dopamine D1 and D3 receptors. The benzoazepine compound and pharmacologically acceptable inorganic or organic salts thereof have a structure shown as formula (I). Results of drug experiments carried out by the invention show that the benzoazepine compound and its pharmacologically acceptable inorganic or organic salts have high antagonistic activity on dopamine D1 and D3, can be used as drug leads for further development of dopamine receptor antagonists with good selectivity and high activity, and can be used as potential drugs for treatment of drug addiction by dopamine D1, D3 receptor antagonists. (formula (I)).

Functional reversal of (?)-Stepholidine analogues by replacement of benzazepine substructure using the ring-expansion strategy

Li, Wei,Zhang, Li,Xu, Lili,Yuan, Congmin,Du, Peng,Chen, Jiaojiao,Zhen, Xuechu,Fu, Wei

, p. 599 - 607 (2016/10/06)

(?)-Stepholidine is an active ingredient of the Chinese herb Stephania and naturally occurring tetrahydroprotoberberine alkaloid with mixed dopamine receptor D1 agonistic and dopamine receptor D2 antagonistic activities. In this work, a series of novel hexahydrobenzo[4,5]azepino [2,1-a]isoquinolines were designed and synthesized as ring-expanded analogues of (?)-Stepholidine. Initial pharmacological assays demonstrated that a benzazepine replacement was associated with significant increase in selectivity and functional reversal at dopamine receptor D1. Compound-(?)-15e (Ki?=?5.32?±?0.01?nm) is more potent than (?)-Stepholidine (Ki?=?13?nm) and was identified as a selective dopamine receptor D1 antagonist (IC50?=?0.14?μm). Moreover, molecular modeling suggested that (?)-15e might exert its dopamine receptor D1 antagonistic activities through interacting with the transmembrane helix 7 of dopamine receptor D1.

PROCESS FOR THE SYNTHESIS OF BENZAZEPINE DERIVATIVES

-

Page/Page column 14-15, (2016/06/21)

Process for the synthesis of benzazepine derivatives The invention relates to a process for the synthesis of 7,8-dimethoxy-1,3-dihydro- benzazepin-2-one of formula (II), as well as to a process for the synthesis of compound of formula (I).

PROCESS FOR THE SYNTHESIS OF 7,8-DIMETHOXY-1,3-DIHYDRO-2H-3-BENZAZEPIN-2-ONE COMPOUNDS, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE

-

, (2014/10/16)

Process for the synthesis of the compound of formula (I): wherein R represents a para-methoxybenzyl (PMB) group or the following group: Application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid.

PROCESS FOR PREPARATION OF IVABRADINE

-

Page/Page column 17-18, (2010/07/09)

The present invention describes a new process for optical resolution of [N-[[3,4- dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]-N-methylamine] which is an intermediate in the preparation of ivabradine.

Synthesis and biological activity of some 1,3-dihydro-2H-3-benzazepin-2- ones with a piperazine moiety as bradycardic agents

Liang, Hong-Yu,Zhang, Deng-Qing,Yue, Yun,Shi, Zhe,Zhao, Sheng-Yin

scheme or table, p. 114 - 119 (2010/06/13)

A series of 1,3-dihydro-2H-3-benzazepin-2-ones with a piperazine moiety were designed and synthesized by treating the common intermediate of 1,3-dihydro-7,8-dimethoxy-3-[3-(1-piperazinyl)-propyl]-2H-3-benzazepin-2-ones with a variety of N-aryl-2-chloroacetamides and acyl chlorides. Their structures have been characterized by 1H-NMR, MS, and elemental analysis. The title compounds were evaluated for their bradycardic activity in vitro. Most of the synthesized compounds exhibited some vasorelaxant activity and heart-rate-reducing activity with bradycardic potency.

A new synthetic approach towards isoquinobenzazepinone and isoindolinobenzazepinone using acid-mediated cyclisation and Heck reaction

Phakhodee, Wong,Ploypradith, Poonsakdi,Sahakitpichan, Poolsak,Ruchirawat, Somsak

experimental part, p. 351 - 356 (2009/04/06)

Six-membered ring cyclisation of N-ethylbenzazepinone, prepared from the condensation of benzazepinone with phenethyl iodide under basic conditions, smoothly provided the corresponding product, isoquino[1,2-b][3]benzazepinone, under acid-mediated conditions. On the other hand, the attempted direct five-membered ring cyclisation using the acid-mediated conditions failed to give the 7,5 fused ring isoindolinobenzazepinone from N-benzylbenzazepinone, but the 7,6 fused ring product was instead obtained. However, five-membered ring cyclisation of N-benzylbenzazepinone could be effected efficiently by employing the Heck reaction followed by catalytic hydrogenation to furnish the desired isoindolinobenzazepinone.

HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS

-

Page/Page column 87, (2009/03/07)

The present invention related to novel heterocyclic amide compounds of Formula 1: as disclosed herein or a pharmaceutically accept able salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosedare compositions comprising said compounds, and methods for using said compounds for treating or preventing a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal disease

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 73942-87-7